MLH1 and neoplasm: Testing for MLH1 epimutation has been recommended in CRC cases diagnosed < 60 years with an MLH1 methylated tumour and those with a history of more than one Lynch-associated tumour [10], although it is unclear how routinely these criteria are applied, primarily due to their rarity.